Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Psychiatric aspects in Parkinsonism treated with L-dopa.

Literature DB >> 5127432

Psychiatric aspects in Parkinsonism treated with L-dopa.

Abstract

Psychiatric aspects of patients with Parkinsonism treated with L-dopa are described. These include acute psychosis in patients with or without previous psychiatric illness and worsening or improvement of pre-existing psychiatric conditions. Therapeutic management is discussed The relevance of these studies to the understanding of the psychiatric aspects of Parkinsonism in general is discussed.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1971 PMID： 5127432 PMCID： PMC493859 DOI： 10.1136/jnnp.34.5.502

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

17 in total

1. Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.

Authors: F K Goodwin; H K Brodie; D L Murphy; W E Bunney
Journal: Lancet Date: 1970-05-02 Impact factor: 79.321

2. Modification of Parkinsonism--chronic treatment with L-dopa.

Authors: G C Cotzias; P S Papavasiliou; R Gellene
Journal: N Engl J Med Date: 1969-02-13 Impact factor: 91.245

3. L-dopa in idiopathic parkinsonism.

Authors: D B Calne; G M Stern; A S Spiers; D R Laurence
Journal: Lancet Date: 1969-11-08 Impact factor: 79.321

4. L-dopa in postencephalitic parkinsonism.

Authors: D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal: Lancet Date: 1969-04-12 Impact factor: 79.321

5. Stereotyped activities produced by amphetamine in several animal species and man.

Authors: A Randrup; I Munkvad
Journal: Psychopharmacologia Date: 1967

6. Critical analysis of the disability in Parkinson's disease.

Authors: D D Webster
Journal: Mod Treat Date: 1968-03

7. Treatment of parkinsonism with levodopa.

Authors: M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal: Arch Neurol Date: 1969-10

8. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease.

Authors: R S Schwab; I Zieper
Journal: Psychiatr Neurol (Basel) Date: 1965

9. Parkinsonism: onset, progression and mortality.

Authors: M M Hoehn; M D Yahr
Journal: Neurology Date: 1967-05 Impact factor: 9.910

10. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

Authors: F McDowell; J E Lee; T Swift; R D Sweet; J S Ogsbury; J T Kessler
Journal: Ann Intern Med Date: 1970-01 Impact factor: 25.391

16 in total

Review 1. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors: Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal: Neurosci Biobehav Rev Date: 2010-07-06 Impact factor: 8.989

2. Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors: A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal: J Neural Transm (Vienna) Date: 1996 Impact factor: 3.575

3. Prevalence of psychotic symptoms in a community-based Parkinson disease sample.

Authors: Joel Mack; Peter Rabins; Karen Anderson; Susanne Goldstein; Stephen Grill; Elaina S Hirsch; Susan Lehmann; John T Little; Russell L Margolis; Justin Palanci; Gregory Pontone; Howard Weiss; James R Williams; Laura Marsh
Journal: Am J Geriatr Psychiatry Date: 2012-02 Impact factor: 4.105

Psychiatric aspects in Parkinsonism treated with L-dopa.

1. Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.

2. Modification of Parkinsonism--chronic treatment with L-dopa.

3. L-dopa in idiopathic parkinsonism.

4. L-dopa in postencephalitic parkinsonism.

5. Stereotyped activities produced by amphetamine in several animal species and man.

6. Critical analysis of the disability in Parkinson's disease.

7. Treatment of parkinsonism with levodopa.

8. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease.

9. Parkinsonism: onset, progression and mortality.

10. Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

Review 1. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

2. Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

3. Prevalence of psychotic symptoms in a community-based Parkinson disease sample.

4. Management of parkinson's disease--combined therapy with levodopa and thalamotomy.

5. Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease.

6. Psychosis and concurrent impulse control disorder in Parkinson's disease: A review based on a case report.

7. The pattern of depressive symptoms varies with progression of Parkinson's disease.

8. Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus.

9. Depression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPA.

Review 10. Visual hallucinations in the elderly associated with the use of levodopa.